Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Pilar Garrido(Hospital Universitario Ramón y Cajal), Fernando López‐Ríos(Hospital Universitario 12 De Octubre)
Cited by 104
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
|Annals of Oncology|2020|313
A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry
|PLoS ONE|2012|107